HOXA9 and glioblastoma: In order to confirm the link between HOXA9-mediated BCL2 overexpression and resistance to temozolomide, and to explore novel combinatorial treatments to GBM, we evaluated how ABT-737, a potent small molecular inhibitor of BCL2 family proteins, affects the response of U87MG cells to temozolomide.